In This Article:
Agenus Inc. (NASDAQ:AGEN) shares are trading higher in the morning session on Wednesday.
The company has secured a $22 million non-amortizing mortgage, backed by its Berkeley-based Biologics CMC facility and its 66-acre biomanufacturing-zoned property in Vacaville, California.
The deal, facilitated by L&L Capital, provides $20 million in net proceeds after closing costs and interest reserve, boosting Agenus’ cash position ahead of anticipated further cash infusions in the coming months.
The mortgage is structured with a two-year term, carrying interest rates of 12% for the first year and 13% for the second, with payments split 50% in cash and 50% in common stock.
In parallel, Agenus is executing a Strategic Operational Realignment Plan to focus its efforts on its promising botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer (CRC).
The plan includes a projected 60% reduction in annual external expenditures and a transition of the company’s CMC capabilities into a fee-for-service biologics manufacturing business. These measures, along with additional planned optimizations, are expected to reduce Agenus’ FY 2025 cash burn to approximately $100 million.
BOT/BAL has demonstrated strong clinical activity in MSS CRC and other cancers resistant to existing therapies. Agenus is preparing for late-stage development and regulatory strategies, targeting both regional and global registration pathways. The company’s strategic realignment aims to revolutionize cancer treatment while positioning Agenus for long-term growth and patient impact.
Price Action: AGEN shares are trading higher by 16.3% to $3.93 at last check Wednesday.
Read next:
-
JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On
Image via Unsplash.
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.